Profund Advisors LLC Lowers Holdings in Immunome, Inc. $IMNM

Profund Advisors LLC lowered its position in Immunome, Inc. (NASDAQ:IMNM) by 23.4% during the 2nd quarter, Holdings Channel reports. The firm owned 16,537 shares of the company’s stock after selling 5,064 shares during the quarter. Profund Advisors LLC’s holdings in Immunome were worth $154,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd bought a new stake in Immunome during the 1st quarter valued at $95,000. Brighton Jones LLC purchased a new position in shares of Immunome during the second quarter valued at $98,000. KLP Kapitalforvaltning AS raised its holdings in shares of Immunome by 140.8% in the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company’s stock valued at $115,000 after acquiring an additional 10,000 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in Immunome by 49.0% in the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company’s stock worth $117,000 after acquiring an additional 5,712 shares during the period. Finally, Arizona State Retirement System grew its holdings in Immunome by 66.2% during the 1st quarter. Arizona State Retirement System now owns 18,764 shares of the company’s stock worth $126,000 after acquiring an additional 7,476 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Stock Up 3.8%

Shares of IMNM opened at $17.14 on Monday. The company has a 50 day moving average of $13.54 and a two-hundred day moving average of $10.81. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -5.81 and a beta of 1.96. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $18.46.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, sell-side analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IMNM shares. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Craig Hallum assumed coverage on shares of Immunome in a research note on Friday, September 5th. They issued a “buy” rating and a $26.00 price objective for the company. Evercore ISI assumed coverage on Immunome in a report on Friday, August 22nd. They set an “outperform” rating and a $18.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group started coverage on Immunome in a research note on Monday, September 22nd. They set a “buy” rating and a $26.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.44.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.